We are monitoring the impact of COVID-19 on LATAM Bladder Cancer Therapeutics Market Get in touch with us for detailed analysis Know More
Share on

Latin America Bladder Cancer Therapeutics Market Research Report – Segmented By Type, Treatment and Country (Brazil, Argentina, Chile and Rest of Latin America) – Industry Size, Share, Trends and Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 1089
Pages: 142

LATAM Bladder Cancer Therapeutics Market Size (2022 to 2027)

The size of the Bladder Cancer Therapeutics market in Latin America is expected to reach USD 43.49 million by 2027 from USD 33.78 million in 2022, growing at a CAGR of 5.18% from 2022 to 2027.

Bladder cancer is the sixth most frequently diagnosed male cancer and the ninth leading cause of cancer death worldwide.

Factors such as technological advancements, innovative treatments, advanced healthcare services, increased awareness of people about cancer therapies, and rising healthcare spending will drive the bladder cancer therapy market. Factors such as the growing influence of specific biologics, the introduction of new drugs, and the acceptance of effective diagnostic tools may increase the LATAM market demand for bladder cancer therapies. Bladder cancer is very common and increases with age. According to a 2020 report from Cancer Research UK, the incidence of bladder cancer increases with age. Besides, the geriatric population in Latin American countries is expected to increase in the future, according to a 2020 United Nations report titled “Aging World Population” 2020.

The most advanced treatment modalities for bladder cancer include immunotherapy, but the most widely used modality for bladder cancer is radiation therapy. Due to the historical prevalence of radiotherapy used in various forms of cancer and because chemotherapy is associated with low specificity and side effects. Radiation therapy also provides best-in-class efficacy in terms of dose frequency and price compared to other therapeutic modalities in bladder cancer treatment. Advances in radiotherapy and the expected increase in the number of patients with bladder cancer are expected to contribute to this market's growth.

The high costs of bladder cancer therapies and the disease's asymptomatic nature may slow market growth.

This research report on the Latin America Bladder Cancer Therapeutics market has been segmented & sub-segmented the market into the following categories:

  • By Type: Transitional Cell Bladder Cancer, Non-Muscle Invasive/Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer, Adenocarcinoma of the Bladder, and Rare Bladder Cancers
  • By Country: Brazil, Argentina, Chile, and Rest of Latin America

Regional Analysis:

The Latin American bladder cancer therapeutics market is estimated to hike at a steady growth rate during the forecast period. According to data from the World Health Organization (2020), the number of new bladder cancer cases in Brazil was 10,214, about 4.1% of all cancers in 2020. In recent years, awareness of bladder disease and its management has improved dramatically, especially in developing regions such as Latin America. Besides, the rise of different therapies such as immunotherapy in cancer treatment has rekindled the interest of eligible patients as it is a newly developed treatment modality and has fewer side effects than radiation therapy and chemotherapy, which are options conventional therapies in the treatment of bladder cancer. Therefore, with the growing awareness of bladder cancer and related therapies, the market for bladder cancer diagnostics and therapies in Latin America is expected to grow in the near future. Apart from this, factors such as increasing healthcare expenditure and innovations in developing new drugs.

Key companies leading the LATAM Bladder Cancer Therapeutics Market profiled in this report are Sanofi S.A. (France), Novartis AG (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and Celgene Corporation (U.S.).

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Type                        

                                5.1.1 Transitional Cell Bladder Cancer    

                                5.1.2 Non Muscle Invasive/Superficial Bladder Cancer     

                                5.1.3 Invasive Bladder Cancer    

                                5.1.4 Squamous Cell Bladder Cancer       

                                5.1.5 Adenocarcinoma of the Bladder    

                                5.1.6 Rare Bladder Cancers         

                5.2 By Treatment                            

                                5.2.1 Surgery    

                                                5.2.1.1 Transurethral Bladder Tumor Resection (TURBT)

                                                5.2.1.2 Cystectomy

                                                5.2.1.3 Urinary Diversion

                                5.2.2 Chemotherapy     

                                5.2.3 Immunotherapy   

                                5.2.4 Radiation Therapy

                                5.2.5 Intravesical Therapy           

6. Geographical Analysis                                              

                6.1 Latin America                            

                                6.1.1 Introduction           

                                6.1.2 Brazil         

                                6.1.3 Argentina

                                6.1.4 Mexico     

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 Sanofi S.A. (France)                 

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Novartis AG (Switzerland)                    

                9.3 Pfizer Inc. (U.S.)                       

                9.4 GlaxoSmithKline plc (U.K.)                   

                9.5 Eli Lilly and Company (U.S.)                 

                9.6 AstraZeneca plc (U.K.)                           

                9.7 Bristol-Myers Squibb (U.S.)                 

                9.9 F. Hoffmann-La Roche Ltd. (Switzerland)                       

                9.10 Celgene Corporation (U.S.)               

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Expert Opinions                                         

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. Latin America Bladder Cancer Therapeutics Market, By Region, From 2022 - 2027 (USD Billion)
  2. Latin America Bladder Cancer Therapeutics Market, By Type, From 2022 - 2027 (USD Billion)
  3. Latin America Transitional Cell Bladder Cancer Market, By Region, From 2022 - 2027 (USD Billion)
  4. Latin America Non Muscle Invasive/Superficial Bladder Cancer Market, By Region, From 2022 - 2027 (USD Billion)
  5. Latin America Invasive Bladder Cancer Market, By Region, From 2022 - 2027 (USD Billion)
  6. Latin America Squamous Cell Bladder Cancer Market, By Region, From 2022 - 2027 (USD Billion)
  7. Latin America Adenocarcinoma of the Bladder Market, By Region, From 2022 - 2027 (USD Billion)
  8. Latin America Rare Bladder Cancers Market, By Region, From 2022 - 2027 (USD Billion)
  9. Latin America Bladder Cancer Therapeutics Market, By Treatment, From 2022 - 2027 (USD Billion)
  10. Latin America Bladder Cancer Surgery Market, By Region, From 2022 - 2027 (USD Billion)
  11. Latin America Bladder Cancer Chemotherapy Market, By Region, From 2022 - 2027 (USD Billion)
  12. Latin America Bladder Cancer Immunotherapy Market, By Region, From 2022 - 2027 (USD Billion)
  13. Latin America Bladder Cancer Radiation Therapy Market, By Region, From 2022 - 2027 (USD Billion)
  14. Latin America Bladder Cancer Intravesical Therapy Market, By Region, From 2022 - 2027 (USD Billion)
  15. Brazil Bladder Cancer Therapeutics Market, By Type, From 2022 - 2027 (USD Billion)
  16. Brazil Bladder Cancer Therapeutics Market, By Treatment, From 2022 - 2027 (USD Billion)
  17. Argentina Bladder Cancer Therapeutics Market, By Type, From 2022 - 2027 (USD Billion)
  18. Argentina Bladder Cancer Therapeutics Market, By Treatment, From 2022 - 2027 (USD Billion)
  19. Mexico Bladder Cancer Therapeutics Market, By Type, From 2022 - 2027 (USD Billion)
  20. Mexico Bladder Cancer Therapeutics Market, By Treatment, From 2022 - 2027 (USD Billion)
  21. Latin America Bladder Cancer Surgery Market, By Type, From 2022 - 2027 (USD Billion)
  22. Latin America Transurethral Bladder Tumor Resection (TURBT) Market, By Region, From 2022 - 2027 (USD Billion)
  23. Latin America Bladder Cancer Cystectomy Market, By Region, From 2022 - 2027 (USD Billion)
  24. Latin America Bladder Cancer Urinary Diversion Market, By Region, From 2022 - 2027 (USD Billion)
  25. Brazil Bladder Cancer Surgery Market, By Type, From 2022 - 2027 (USD Billion)
  26. Argentina Bladder Cancer Surgery Market, By Type, From 2022 - 2027 (USD Billion)
  27. Mexico Bladder Cancer Surgery Market, By Type, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample